Treatment for COVID-19

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Cyn3rgy Research, Gresham, OR
COVID-19
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

Performance of the LumiraDx SARS-CoV-2 Ag ULTRA assay will be assessed by comparison to a reference method

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for COVID-19

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 4 months

4 months
Performance Evaluation

Trial Safety

Safety Progress

1 of 3

Other trials for COVID-19

Trial Design

0 Treatment Group

400 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 4 months
Closest Location: Cyn3rgy Research · Gresham, OR
2011First Recorded Clinical Trial
3 TrialsResearching COVID-19
30 CompletedClinical Trials

Eligibility Criteria

Age Any Age · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You may enroll in any age or gender.\n
You are capable and willing to give informed consent/assent.
You are asymptomatic and have not experienced signs or symptoms within the past 14 days.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.